Company intelligence / Profile preview

Pentra

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Pentra Therapeutics is a clinical-stage biotechnology company dedicated to developing novel therapies for patients suffering from life-threatening fibrotic and inflammatory diseases. The company's lead program is a recombinant human Pentraxin-2 (PTX-2) protein therapy, which is designed to regulate the body's natural healing processes and prevent the progression of fibrosis. Pentra is currently advancing its lead candidate through clinical trials for indications such as idiopathic pulmonary fibrosis (IPF) and myelofibrosis. Founded by industry veterans with deep expertise in pentraxin biology, the company aims to address significant unmet medical needs in the treatment of chronic scarring and inflammation.

Therapeutic areas: HematologyImmunologyPulmonologyOther
Modalities: Recombinant proteinProtein
Industry: Biotech

Beyond the preview

Go deeper on Pentra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pentra.

Explore the full profile